- US12459967utility2025Modulators of 5′-nucleotidase, Ecto and the Use Thereof0 cites
- US12453738utility2025Treatment of Oncogene-driven Cancers0 cites
- US12433836utility2025Parenterally Administered Immune Enhancing Drugs0 cites
- US12415854utility2025Antibodies to TIGIT0 cites
- US12410170utility20252,3,5-trisubstituted Pyrazolo[1,5-a]pyrimidine Compounds0 cites
- US12384773utility2025Thiazole Compounds and Methods of Use Thereof0 cites
- US12310965utility2025Treatment of Cancer Utilizing an Identified Adenosine Fingerprint0 cites
- US12281136utility2025Crystalline Forms of a CD73 Inhibitor and Uses Thereof0 cites
- US12226425utility2025Inhibitors of ARG1 And/or ARG20 cites
- US12195447utility2025Azolopyrimidine for the Treatment of Cancer-related Disorders0 cites
- US12195482utility2025Compounds as Inhibitors of AXL0 cites
- US12168023utility2024Inhibitors of Adenosine 5′-nucleotidase0 cites
- US12145901utility2024Process for Preparing Tetralin Compounds0 cites
- US12103907utility2024Tetralin and Tetrahydroquinoline Compounds as Inhibitors of Hif-2alpha0 cites
- US12071411utility2024Inhibitors of Hif-2α and Methods of Use Thereof0 cites
- US12064433utility2024Pyridone A2R Antagonists0 cites
- US12054500utility2024Arginase Inhibitors0 cites
- US11993584utility2024Solid Forms of an Azolopyrimidine Compound0 cites
- US11931343utility2024CD73 Inhibitors0 cites
- US11819512utility2023Solid Forms of a CD73 Inhibitor and the Use Thereof0 cites
Page 1 of 2Next →